IDEAYA Biosciences (NASDAQ:IDYA) Announces Earnings Results, Beats Expectations By $0.04 EPS

IDEAYA Biosciences (NASDAQ:IDYA) issued its quarterly earnings results on Tuesday. The company reported ($0.53) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.04, MarketWatch Earnings reports.

Shares of IDYA opened at $4.12 on Wednesday. The stock’s fifty day moving average price is $6.24 and its two-hundred day moving average price is $7.45. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.86 and a current ratio of 18.86. IDEAYA Biosciences has a 1 year low of $2.95 and a 1 year high of $16.90.

A number of analysts recently commented on IDYA shares. ValuEngine upgraded IDEAYA Biosciences from a “hold” rating to a “buy” rating in a report on Tuesday, March 3rd. Zacks Investment Research lowered IDEAYA Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 18th. Finally, Roth Capital started coverage on IDEAYA Biosciences in a report on Friday, March 13th. They set a “buy” rating and a $12.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $16.82.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Further Reading: What is a Swap?

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with's FREE daily email newsletter.